The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.
- 31 Oct 2016 Planned initiation date changed from 1 Aug 2016 to 30 Nov 2016.